Literature DB >> 8724890

Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran.

A J Apperloo1, D de Zeeuw, A J Donker, P E de Jong.   

Abstract

In studies on the progression of chronic renal failure the measurement of GFR must be very reliable. Sequential determination of GFR using the renal clearances of exogenous tracers such as inulin or iothalamate is the most accepted method. However, because of inaccuracies in urine collection, intratest variation, and thus intertest variation, of these clearances is considerable. This has a negative impact on the precision of long-term slope estimations. A previously described method of GFR determination on the basis of simultaneous infusion of 131I-hippuran and 125I-iothalamate corrects for inaccurate urine collection. To study whether this correction method improves the precision of the GFR slope measurement, this study analyzed longitudinal GFR data obtained in 71 patients with renal disease during a follow-up of 84 to 180 wk (477 renal function studies). All GFR were calculated by using both the standard renal clearance method and the correction method. The intratest and intertest coefficient of variation was significantly smaller for the correction method compared with the standard method (1.93 +/- 0.20 versus 8.48 +/- 1.66% P < 0.0005; and 2.88 +/- 0.32 versus 5.12 +/- 0.66%, P < 0.005, respectively). As a result, the precision of the GFR slope estimation was significantly better with the correction method compared with the standard method (error of the slope, 1.63 +/- 1.09 versus 2.35 +/- 2.36 mL/min per yr, P < 0.01). This improvement in precision of the slope by using the correction method reduces the necessary sample size needed to detect a GFR slope difference between interventions to about 30% of that needed when using the standard method. It is concluded that the precision of GFR measurements is improved by using correction for inaccurate urine collection with concomitant 131I-hippuran clearance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724890     DOI: 10.1681/ASN.V74567

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  24 in total

1.  The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.

Authors:  A C Vedder; G E Linthorst; M J van Breemen; J E M Groener; F J Bemelman; A Strijland; M M A M Mannens; J M F G Aerts; C E M Hollak
Journal:  J Inherit Metab Dis       Date:  2007-01-05       Impact factor: 4.982

2.  Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size.

Authors:  Wieneke Marleen Michels; Diana Carina Grootendorst; Marion Verduijn; Elise Grace Elliott; Friedo Wilhelm Dekker; Raymond Theodorus Krediet
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 8.237

3.  Development and validation of a new statistical model for prognosis of long-term graft function after pediatric kidney transplantation.

Authors:  Lars Pape; Thurid Ahlenstiel; Christin D Werner; Antonia Zapf
Journal:  Pediatr Nephrol       Date:  2012-11-07       Impact factor: 3.714

4.  Central body fat distribution associates with unfavorable renal hemodynamics independent of body mass index.

Authors:  Arjan J Kwakernaak; Dorien M Zelle; Stephan J L Bakker; Gerjan Navis
Journal:  J Am Soc Nephrol       Date:  2013-04-11       Impact factor: 10.121

5.  Renal function equations before and after living kidney donation: a within-individual comparison of performance at different levels of renal function.

Authors:  Hilde Tent; Mieneke Rook; Lesley A Stevens; Willem J van Son; L Joost van Pelt; H Sijbrand Hofker; Rutger J Ploeg; Jaap J Homan van der Heide; Gerjan Navis
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 8.237

6.  Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study.

Authors:  Bruce A Perkins; Robert G Nelson; Betsy E P Ostrander; Kristina L Blouch; Andrzej S Krolewski; Bryan D Myers; James H Warram
Journal:  J Am Soc Nephrol       Date:  2005-03-23       Impact factor: 10.121

7.  Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.

Authors:  Debbie Zittema; Else van den Berg; Esther Meijer; Wendy E Boertien; Anneke C Muller Kobold; Casper F M Franssen; Paul E de Jong; Stephan J L Bakker; Gerjan Navis; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

8.  Cystatin C--a paradigm of evidence based laboratory medicine.

Authors:  Janice S C Chew; Mohammed Saleem; Christopher M Florkowski; Peter M George
Journal:  Clin Biochem Rev       Date:  2008-05

9.  The influence of the ACE ( I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric Type 1 diabetes mellitus.

Authors:  P T Luik; K Hoogenberg; M N Kerstens; B J Beusekamp; P E De Jong; R P F Dullaart; G J Navis
Journal:  Diabetologia       Date:  2003-07-10       Impact factor: 10.122

10.  Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients.

Authors:  Niek F Casteleijn; A Lianne Messchendorp; Kyong T Bae; Eiji Higashihara; Peter Kappert; Vicente Torres; Esther Meijer; Anna M Leliveld
Journal:  Clin Exp Nephrol       Date:  2016-06-23       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.